Amphastar Pharmaceuticals Inc diskutieren

klostergang stimmt dem Sentiment von 'Buy' zu

The Company currently has three abbreviated new drug applications, or ANDAs filed with the FDA, targeting products with a market size of over $0.5 billion, three biosimilar products in development targeting products with a market size of $15.0 billion, and 11 generic products in development targeting products with a market size of over $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2017. The Company's proprietary pipeline includes NDAs for Primatene

^®

Mist and intranasal naloxone. The Company is currently developing several other proprietary products with various dosage forms.